keyword
MENU ▼
Read by QxMD icon Read
search

locally advanced lung cancer surgery

keyword
https://www.readbyqxmd.com/read/29895214/afatinib-with-subsequent-surgery-in-stage-iii-nsclc-with-egfr-mutation-lessons-learned-from-two-clinical-experiences
#1
Francesca Mazzoni, Paolo Petreni, Marco Perna, Vieri Scotti, Stefano Bongiolatti, Lorenzo Livi, Francesco Di Costanzo, Luca Voltolini
Afatinib, a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is effective as first-line treatment in patients with EGFR-mutated non-small cell lung cancer (NSCLC). We report 2 cases of EGFR-mutated locally advanced NSCLC treated in neoadjuvant setting with EGFR tyrosine kinase inhibitor at University of Florence/Careggi Hospital. In both cases, afatinib was used for up to 3 months, until 1 week before surgery. Both patients achieved significant reduction (downstaging) of the pulmonary mass and lymphadenopathies and after surgery, it was decided for both cases to restore afatinib treatment up to a further 4 months...
June 1, 2018: Tumori
https://www.readbyqxmd.com/read/29881714/mechanisms-and-therapy-for-cancer-metastasis-to-the-brain
#2
REVIEW
Federica Franchino, Roberta Rudà, Riccardo Soffietti
Advances in chemotherapy and targeted therapies have improved survival in cancer patients with an increase of the incidence of newly diagnosed brain metastases (BMs). Intracranial metastases are symptomatic in 60-70% of patients. Magnetic resonance imaging (MRI) with gadolinium is more sensitive than computed tomography and advanced neuroimaging techniques have been increasingly used in the detection, treatment planning, and follow-up of BM. Apart from the morphological analysis, the most effective tool for characterizing BM is immunohistochemistry...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29806826/treatment-of-liver-metastases-using-an-internal-target-volume-method-for-stereotactic-body-radiotherapy
#3
Wei-Jun Wang, Jeng-Fong Chiou, Yaoru Huang
The prognosis of patients with metastatic cancers has improved in the past decades due to effective chemotherapy and oligometastatic surgery. For inoperable patients, local ablation therapies, such as stereotactic body radiotherapy (SBRT), can provide effective local tumor control with minimal toxicity. Because of its high precision and accuracy, SBRT delivers a higher radiation dose per fraction, is more effective, and targets smaller irradiation volumes than does conventional radiotherapy. In addition, steep dose gradients from target lesions to surrounding normal tissues are achieved using SBRT; thus, SBRT provides more effective tumor control and exhibits fewer side effects than conventional radiotherapy...
May 8, 2018: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/29805772/prognostic-factors-of-afatinib-as-a-first-line-therapy-for-advanced-egfr-mutation-positive-lung-adenocarcinoma-a-real-world-large-cohort-study
#4
Sheng-Kai Liang, Meng-Rui Lee, Wei-Yu Liao, Chao-Chi Ho, Jen-Chung Ko, Jin-Yuan Shih
Lung cancer remains the primary cause of cancer-related mortality worldwide. Several treatment modalities are available for lung cancer, including surgery, radiation, and chemotherapy. Among the chemotherapeutics available, afatinib has been shown to be effective for those with epidermal growth factor receptor ( EGFR ) mutation-positive lung adenocarcinoma. Herein, we analyzed the factors affecting the prognosis of patients who received afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma in the real-world setting...
May 4, 2018: Oncotarget
https://www.readbyqxmd.com/read/29785291/using-novel-technology-to-augment-complex-video-assisted-thoracoscopic-single-basilar-segmentectomy
#5
Zaid M Abdelsattar, Shanda H Blackmon
There are many novel technologies that enable complex segmentectomy to be performed. As lung cancer screening becomes more prevalent, patients are increasingly diagnosed with early stage lung cancer, multifocal disease, and second primary tumors. This shift to an earlier clinical presentation combined with advances in technology and an emphasis on minimally invasive techniques have led to the current developments we are now seeing with anatomic segmentectomy. In this paper, we describe the operative technique of an indocyanine green (ICG)-guided video-assisted thoracoscopic surgery (VATS) single basilar segmental resection, augmented with methylene blue dye marker localization via SuperDimension electromagnetic navigational bronchoscopy...
April 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29760563/durvalumab-a-potential-maintenance-therapy-in-surgery-ineligible-non-small-cell-lung-cancer
#6
REVIEW
Michael R Shafique, Lary A Robinson, Scott Antonia
Lung cancer is the most common cancer worldwide and the most common cause of cancer-related death. Non-small-cell lung cancer comprises ~87% of newly diagnosed cases of lung cancer, and nearly one-third of these patients have stage III disease. Despite improvements in the treatment of stage IV lung cancer, particularly with the introduction and dissemination of checkpoint inhibitors, very little progress has been made in the treatment of stage III lung cancer. In this article, we discuss the general staging criteria and treatment options for stage III lung cancer...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29757872/pattern-of-care-health-care-disparities-and-their-impact-on-survival-outcomes-in-stage-ivb-cervical-cancer-a-nationwide-retrospective-cohort-study
#7
Randa J Jalloul, Shelly Sharma, Celestine S Tung, Barrett OʼDonnell, Michelle Ludwig
OBJECTIVE: Although locally advanced cervical cancer can be cured, patients with stage IVB disease have poor prognosis with limited treatment options. Our aim was to describe the pattern of care and analyze health disparity variables that may account for differences in treatment modalities and survival in this population. METHODS: The National Cancer Database was queried for patients diagnosed between 2004 and 2013 with metastatic squamous cell carcinoma or adenocarcinoma of the cervix...
May 4, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29755103/-when-should-we-perform-surgery-for-n2-lung-cancer-induction-chemoradiotherapy-or-surgery-for-local-recurrence-or-residual-tumor-after-definitive-chemoradiotherapy
#8
Hiroyuki Ito, Haruhiko Nakayama
BACKGROUND: Standard treatment for locally advanced clinical N2 lung cancer is definitive chemoradiotherapy, and induction chemoradiotherapy(IND-CRT) followed by surgery is an option. Most of them recurs remotely within a few years after initial therapy. Patients who received salvage surgery(SAL) after definitive chemoradiotherapy had no remote relapse for some period after definitive chemoradiotherapy, thus the outcome of SAL may be better than those of IND-CRT, but the operative risks of both procedures seem to be high...
April 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/29755101/-outcome-of-surgical-treatment-of-locally-advanced-lung-cancer-after-induction-chemoradiotherapy
#9
Masayuki Tanahashi, Haruhiro Yukiue, Eriko Suzuki, Naoko Yoshii, Shinsuke Kitazawa, Yasunori Kaminuma, Hiroshi Niwa
OBJECTIVE: The outcome of surgical treatment of non-small-cell lung cancer after induction chemoradiotherapy was investigated. SUBJECTS: The subjects were 74 patients with non-small-cell lung cancer who received induction chemoradiotherapy( ICRT) between 1998 and 2016. ICRT was administered to pT3 lung cancer invading the chest wall(20 patients), pT4 lung cancer invading the adjacent organ(22 patients), and cN2 lung cancer(32 patients). cN2 was confirmed by mediastinoscopy(13 patients) and endobronchial ultrasound-guided transbronchial needle aspiration(EBUS-TBNA)(19 patients)...
April 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/29755100/-induction-chemoradiotherapy-for-locally-advanced-non-small-cell-lung-cancer
#10
Akihiro Miura, Junichi Soh, Kazuhiko Shien, Hiromasa Yamamoto, Shinichi Toyooka
The management of locally advanced non-small cell lung cancer (LA-NSCLC) is still controversial, because of complicated patient status and poor prognosis. The purpose of this study was to evaluate the treatment results for induction chemoradiotherapy (iCRT) followed by surgery for LA-NSCLC. From 1999 to 2016, 157 patients were surgically treated after iCRT in our hospital, and their median follow-up was 43 months. Overall survival( OS) was 66.8%, and relapse-free survival( RFS) was 52.0%. The poor prognostic factor in OS by multivariate analysis was lower-lobe origin, incomplete radiotherapy, reoperation, and RFS was lower-lobe origin...
April 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/29755097/-expectation-for-surgery-in-multi-modality-treatment-in-non-small-cell-lung-cancer
#11
Kenji Sugio
Clinical N2-stageⅢA non-small cell lung cancer(NSCLC) is known to be quite heterogeneous. Many clinical trials proved the effect of postoperative adjuvant chemotherapy for locally advanced NSCLC, which is recommended as grade C1 by Clinical Guideline for Lung Cancer, however, induction treatment for clinical N2-stageⅢA remains still controversial. We showed retrospective data of concurrent chemoradiotherapy using S-1 and cisplatin followed by surgery, which may provide a better prognosis for locally advanced NSCLC patients...
April 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/29740957/egfr-exon-20-insertion-mutation-in-advanced-thymic-squamous-cell-carcinoma-response-to-apatinib-and-clinical-outcomes
#12
Su Yudong, Meng Zhaoting, Wang Xinyue, Lin Li, Xu Xiaoyan, Zuo Ran, Chen Jinliang, Chen Peng
Thymic carcinoma (TC) is a rare malignant tumor of the mediastinum with occult onset, rapid development, and poor prognosis. Surgery is the main treatment for early TC, but the majority of patients are diagnosed at Masaoka-Koga stage III or IV with local invasion or distant metastasis. Platinum and anthracyclines are currently considered key components of first-line chemotherapy for advanced TC; however, there are no standard treatment plans for patients who are refractory to first-line and further chemotherapy...
May 8, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29729581/immune-prophets-of-lung-cancer-the-prognostic-and-predictive-landscape-of-cellular-and-molecular-immune-markers
#13
REVIEW
Ivana Catacchio, Anna Scattone, Nicola Silvestris, Anita Mangia
Lung cancer is the leading cause of cancer deaths throughout the world. The majority of patients are diagnosed with locally advanced or metastatic disease when surgery, the best curative option, is no longer feasible. Thus, the prognosis of lung cancer remains poor and heterogeneous and new biomarkers are needed. As the immune system plays a pivotal role in cancer, the study of tumor microenvironment, with regard to the immune component, may provide valuable information for a better comprehension of the pathogenesis and progression of the disease...
May 2, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29718155/robotic-resection-of-stage-iii-lung-cancer-an-international-retrospective-study
#14
Giulia Veronesi, Bernard Park, Robert Cerfolio, Mark Dylewski, Alpert Toker, Jacques P Fontaine, Wael C Hanna, Emanuela Morenghi, Pierluigi Novellis, Frank O Velez-Cubian, Marisa H Amaral, Elisa Dieci, Marco Alloisio, Eric M Toloza
OBJECTIVES: Minimally invasive surgery is accepted for early-stage lung cancer, but its role in locally advanced disease is controversial, especially using a robotic platform. The aim of this retrospective study was to assess the safety and effectiveness of robot-assisted resection in patients with Stage IIIA non-small-cell lung cancer (NSCLC) or carcinoid tumours in the series as a whole and in different subgroups according to adjuvant treatment. METHODS: This was a retrospective multicentre study of consecutive patients with clinically evident or occult N2 disease (210 NSCLC and 13 carcinoid) who, in 2007-2016, underwent robot-assisted resection at 7 high-volume centres...
April 30, 2018: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/29690894/uniportal-video-assisted-thoracoscopic-surgery-following-neoadjuvant-chemotherapy-for-locally-advanced-lung-cancer
#15
Zhiqiang Yang, Chunbo Zhai
BACKGROUND: Several retrospective studies have confirmed that video-assisted thoracoscopic surgery (VATS) following neoadjuvant chemotherapy is a safe and feasible treatment for advanced non-small cell lung cancer patients. As a minimally invasive technique, VATS usually leads to better clinical outcomes and better compliance with adjuvant treatment than conventional thoracotomy. Uniportal VATS (U-VATS) as an alternative option to conventional multi-port VATS has attracted much attention recently because reduced number and size of incisions may help to decrease inflammatory response and reduce postoperative pain for patients...
April 24, 2018: Journal of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/29682467/extended-uniportal-video-assisted-thoracic-surgery-for-lung-cancer-is-it-feasible
#16
REVIEW
Iñigo Royo-Crespo, Arthur Vieira, Paula A Ugalde
Since the first description of uniportal video-assisted thoracic surgery (U-VATS) (or single-port) lobectomy, several centers in Asia and Europe rapidly adopted this technique as a standard approach for treatment of early stage non-small cell lung cancer (NSCLC). Despite the controversies regarding feasibility and completeness of resection, thoracic surgeons in high volume centers keep pushing the limits to perform very complex procedures also known as "extended resections" through minimally invasive surgery...
2018: Journal of Visualized Surgery
https://www.readbyqxmd.com/read/29681596/is-surgery-after-chemoradiotherapy-feasible-in-lung-cancer-patients-with-superior-vena-cava-invasion
#17
Hiroki Sato, Junichi Soh, Katsuyuki Hotta, Kuniaki Katsui, Susumu Kanazawa, Katsuyuki Kiura, Shinichi Toyooka
PURPOSE: The purpose of this study is to explore the possibility of surgery after chemoradiotherapy (CRT) for locally advanced-non-small-cell lung cancer (LA-NSCLC) with superior vena cava (SVC) resection in terms of prognosis and early and late postoperative course. METHODS: The medical records of NSCLC patients who underwent surgery after CRT at our institution between January 2001 and March 2016 were reviewed. We evaluated the feasibility of surgery with SVC resection after CRT...
April 20, 2018: Annals of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/29666453/epidemiology-and-survival-outcomes-of-mucinous-adenocarcinomas-a-seer-population-based-study
#18
Guang-Dong Xie, Yi-Rong Liu, Yi-Zhou Jiang, Zhi-Ming Shao
To investigate the epidemiology, demographics and survival of mucinous adenocarcinomas (MACs), we identified 80,758 MAC patients in the Surveillance, Epidemiology and End Results (SEER) database. The reported incidence of MACs ebbed and flowed over time; however, a significant increase in reported annual age-adjusted incidences of MACs in the appendix, lung and bronchus was observed from 1981 to 2014. The demographics and outcomes of MACs differed by anatomic sites. MACs of the stomach had the largest percentage of poorly differentiated or undifferentiated tumors (41...
April 17, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29664358/tailored-management-of-stage-iiia-non-small-cell-lung-cancer-in-the-era-of-the-8th-edition-of-the-tnm-classification-for-lung-cancer
#19
Michael R Mueller
Stage IIIA is a very heterogeneous group encompassing locally advanced disease with T3 and T4 tumors without any nodal involvement and very small T1a primary tumors with unilateral mediastinal lymphatic disease. Tailored management defines interdisciplinary management requiring board decisions, which can sometimes be difficult particularly in stage IIIa non-small-cell lung cancer (NSCLC). Lobectomy still is standard of care even for stage I NSCLC, which increasingly is implemented using minimally invasive surgical technique...
March 2018: Future Oncology
https://www.readbyqxmd.com/read/29607193/two-cases-of-combined-thoracoscopy-and-open-chest-surgery-for-locally-advanced-lung-carcinoma
#20
Hitoshi Dejima, Hiroaki Kuroda, Katsutoshi Seto, Shozo Sakata, Takaaki Arimura, Tetsuya Mizuno, Noriaki Sakakura, Yukinori Sakao
Thoracoscopic surgery is becoming more widely used in thoracic surgery and has an increasingly important role to play. However, its use for locally advanced carcinoma (clinical stage T3-4) remains controversial. We adapted our procedure by combining thoracoscopy and open chest surgery (combination surgery) with the aim of reducing invasiveness while ensuring that the operation is safe and curative. Here we describe our experience. Case 1 was a man in his 60s who underwent induction chemoradiotherapy (cisplatin plus vinorelbine plus 40 Gy radiotherapy) followed by radical surgery for a left apical lung carcinoma with chest wall invasion...
February 2018: Journal of Thoracic Disease
keyword
keyword
28518
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"